- Home
- STT vs BIIB Comparison
STT vs BIIB Comparison
Compare STT & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STT
- BIIB
- Stock Information
- Founded
- STT 1792
- BIIB 1978
- Country
- STT United States
- BIIB United States
- Employees
- STT N/A
- BIIB N/A
- Industry
- STT Major Banks
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- STT Finance
- BIIB Health Care
- Exchange
- STT Nasdaq
- BIIB Nasdaq
- Market Cap
- STT 32.3B
- BIIB 18.7B
- IPO Year
- STT N/A
- BIIB 1991
- Fundamental
- Price
- STT $117.65
- BIIB $157.08
- Analyst Decision
- STT Buy
- BIIB Buy
- Analyst Count
- STT 13
- BIIB 24
- Target Price
- STT $127.92
- BIIB $174.62
- AVG Volume (30 Days)
- STT 2.4M
- BIIB 1.6M
- Earning Date
- STT 10-17-2025
- BIIB 10-30-2025
- Dividend Yield
- STT 2.85%
- BIIB N/A
- EPS Growth
- STT 49.61
- BIIB N/A
- EPS
- STT 9.43
- BIIB 10.97
- Revenue
- STT $13,626,000,000.00
- BIIB $10,065,900,000.00
- Revenue This Year
- STT $7.99
- BIIB $2.97
- Revenue Next Year
- STT $4.63
- BIIB N/A
- P/E Ratio
- STT $12.49
- BIIB $14.28
- Revenue Growth
- STT 8.59
- BIIB 4.77
- 52 Week Low
- STT $72.81
- BIIB $110.04
- 52 Week High
- STT $119.33
- BIIB $179.20
- Technical
- Relative Strength Index (RSI)
- STT 56.21
- BIIB 64.92
- Support Level
- STT $113.83
- BIIB $148.90
- Resistance Level
- STT $119.33
- BIIB $155.33
- Average True Range (ATR)
- STT 2.27
- BIIB 4.79
- MACD
- STT 0.11
- BIIB 0.47
- Stochastic Oscillator
- STT 76.67
- BIIB 96.41
About STT State Street Corporation
State Street is a leading provider of financial services, including investment servicing, investment management, and investment research and trading. With approximately $49 trillion in assets under custody and administration, and $5.1 trillion in assets under management, as of June 30, 2025, State Street operates globally in more than 100 geographic markets and employs about 53,000 worldwide.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.